September 16, 2022 News by Lindsey Shapiro, PhD Stem Cell Transplant for MS Eases Fatigue, Improves Life Quality Autologous hematopoietic stem cell transplant (aHSCT) ā commonly called stem cell therapy ā lessens fatigue and improves quality of life in people with highly active relapsing multiple sclerosis (MS), according to a small study in Lithuania. These gains in the physical and social domains of quality of life…
January 14, 2022 News by Yedida Y Bogachkov PhD Trial of Cannabidiol-derived EHP-101 for Relapsing MS Enrolling Soon Emerald Health Pharmaceuticals will soon begin enrollment in a Phase 2a clinical trial investigating its cannabidiol-derived therapy EHP-101 in relapsing forms of multiple sclerosis (MS). The trial (NCT04909502) aims to recruit 50 patients, ages 18-55, with relapsing-remitting MS (RRMS) and active secondary progressive MS (SPMS).
April 13, 2021 News by Patricia Inacio, PhD Phase 3 Trial of GA Depot as Monthly Relapsing MS Therapy Enrolling in US, Europe A Phase 3 trial investigating GA Depot, a long-acting, once-a-month injectable formulation of glatiramer acetate, is seeking patients with relapsing forms of multiple sclerosis (MS). The global study (NCT04121221) aims to include 960 adults, ages 18 to 55, diagnosed withĀ clinically isolated syndromeĀ (CIS),Ā relapsing-remitting…
August 1, 2017 News by Jose Marques Lopes, PhD Long-term Tysabri Treatment Improved Quality of Life and Satisfaction with Therapy in Relapsing MS Patients, Study Finds Long-term Tysabri (natalizumab) treatment of relapsing multiple sclerosis (RMS) improves physical and mental health and leads to greater satisfaction with therapy, new research shows. The study, āLong-term natalizumab treatment is associated with sustained improvements in quality of life in patients with multiple sclerosis,ā appeared in the journal…
July 20, 2016 News by Patricia Silva, PhD Merck KGaA’s Investigational MS Therapy Cladribine Gets EMA Marketing Authorization Application Review Merck KGaA, Darmstadt, GermanyĀ recently announced that the European Medicines Agency (EMA) has accepted for review the Marketing Authorization Application (MAA) of the company’sĀ investigational productĀ Cladribine Tablets as a therapy forĀ relapsing multiple sclerosis (RMS) in Europe. Cladribine is a synthetic antineoplastic agent able to suppress the immune system, causing relatively few…
May 26, 2016 News by Patricia Silva, PhD Sanofi Genzyme Launches vs.MS Global Campaign to Raise Awareness on MS’ Physical and Emotional Burden Sanofi GenzymeĀ recently launched vs.MS, a global initiative to raise awareness of the often unspoken physical and emotional burden of relapsing multiple sclerosis (RMS) on people living with the disease and their care partners. OnĀ World MS DayĀ yesterday, the company called onĀ the MS community to learn more about the…
May 4, 2016 News by Patricia Silva, PhD CHMP Favors European Approval of Zinbryta (Daclizumab) to Treat Relapsing MS The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recently recommended marketing authorization to Zinbryta (daclizumab) for the treatment of patients with relapsing multiple sclerosis (RMS). Zinbryta (daclizumabĀ HYP) is a humanized monoclonal antibody that is injected every four weeks, and being developed by…
October 8, 2015 News by Patricia Silva, PhD Aubagio (Teriflunomide) Slows Brain Atrophy in Patients with Relapsing Multiple Sclerosis GenzymeĀ recently announced results from magnetic resonance imaging (MRI) analysis of participants in the Phase III TEMSO clinical trial showing that AubagioĀ®Ā (teriflunomide) was able to slow the loss of brain volume (or atrophy) versus a placebo over two years in patients with relapsing multiple sclerosis (RMS). Brain volume loss (BVL)…
September 14, 2015 News by Patricia Silva, PhD Merck Prepares to File for European Marketing Authorization for Cladribine Tablets as a Multiple Sclerosis Therapy MerckĀ recently reported its intention to file for European registration of its product candidate forĀ relapsing multiple sclerosis – Cladribine, a synthetic anti-cancer agent able to suppress the immune system. Cladribine causesĀ relatively few side effects and results in very little non-target cell loss. Merck’s decision follows new findingsĀ and further characterization of…
June 19, 2015 News by Kara Elam Biogen and SELF Join Together to Help Women With Relapsing Multiple Sclerosis Re-imagine Daily Life Biogen, a global biotechnology company with over 30 years of clinical excellence in Multiple Sclerosis (MS) research, has recently announced the launch of Reimagine MySelf, a blog dedicated to helping women navigate their daily lives while also dealing with the complications that come with a diagnosis of relapsing MS…
April 14, 2015 News by Patricia Silva, PhD New Novartis Analyses On Gilenya For Relapsing Multiple Sclerosis To Be Presented at Upcoming Conference NovartisĀ will present novelĀ GilenyaĀ data, demonstratingĀ the company’s methods for assessing the impact of relapsing multiple sclerosis (RMS) in bothĀ patients and physicians, during the 67th Annual Meeting of American Academy of Neurology (AAN) that will take place in Washington, DC between the 18th and the 25th of April, 2015. The data will…